NCT04774939

Brief Summary

The aim of the study is to investigate the optimal timing of sclerotherapy for treatment of varicose tributaries on EVLA (endogenous laser ablation) patients.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
350

participants targeted

Target at P75+ for not_applicable

Timeline
47mo left

Started Mar 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress57%
Mar 2021Mar 2030

First Submitted

Initial submission to the registry

February 24, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 1, 2021

Completed
14 days until next milestone

Study Start

First participant enrolled

March 15, 2021

Completed
6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 15, 2027

Expected
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2030

Last Updated

March 1, 2021

Status Verified

February 1, 2021

Enrollment Period

6 years

First QC Date

February 24, 2021

Last Update Submit

February 24, 2021

Conditions

Outcome Measures

Primary Outcomes (4)

  • re-intervention

    Requirement of re-intervention

    3 months

  • Pain after procedure

    Post procedural pain measured with VAS scale

    up to 3 months after the treatment

  • Quality of life before after procedure

    Quality of life will be measured with Veins questionnaire

    up to 5 years

  • Recur

    The recurring varicose veins

    up to 5 years

Secondary Outcomes (1)

  • Surgical complications

    3 months

Study Arms (2)

EVLA only

ACTIVE COMPARATOR

Only main trunk/trunks with venous reflux will be treated

Procedure: Endovenous laser ablation

EVLA and sclerotherapy of tributaries

ACTIVE COMPARATOR

Main trunk/trunks with venous reflux will be treated combined with foam sclerotherapy

Procedure: Endovenous laser ablation

Interventions

The aim is to combine the significance of for sclerotherapy at the primary EVLA treatment

Also known as: Endovenous laser ablation combined with foam sclerotherapy of varicose tributaries
EVLA and sclerotherapy of tributariesEVLA only

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Varicose disease of lower extremity caused by reflux of VSM, SSV or AASV to be treated with EVLA. Age over 18 years. Clinical symptoms C2-3.

You may not qualify if:

  • No severe comorbidities. Previous DVT.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Turku University Hospital

Turku, 20520, Finland

Location

Related Publications (1)

  • Viljamaa J, Firoozi K, Venermo M, Pokela M, Pihlaja T, Halmesmaki K, Hakovirta H. A study protocol for comparing the treatment of varicose tributaries either concomitantly with or separately from endovenous laser ablation of the incompetent saphenous trunk (the FinnTrunk Study). A multicenter parallel-group randomized controlled study. PLoS One. 2023 May 23;18(5):e0285823. doi: 10.1371/journal.pone.0285823. eCollection 2023.

Study Officials

  • Harri Hakovirta, Professor

    University of Turku

    STUDY CHAIR

Central Study Contacts

Harri Hakovirta, Professor

CONTACT

Khalil Firoozi, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

February 24, 2021

First Posted

March 1, 2021

Study Start

March 15, 2021

Primary Completion (Estimated)

March 15, 2027

Study Completion (Estimated)

March 15, 2030

Last Updated

March 1, 2021

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will not share

Locations